New Targeted Therapy Trial Opens, Part of PC-BETS Metastatic CRPC Study

New Targeted Therapy Trial Opens, Part of PC-BETS Metastatic CRPC Study
A trial opened to investigate CFI-400945, by Treadwell Therapeutics, as a potential oral therapy for people with metastatic castration-resistant prostate cancer (mCRPC), the company announced in a press release. It is one of several sub-studies within a larger Phase 2 clinical trial (NCT03385655) that is evaluating various treatment candidates, including targeted therapies, immunotherapies, and chemotherapies, as possible precision treatments for mCRPC patients. People enrolled first undergo a liquid biopsy to identify specific mutations evident in cancer cell DNA that is circulating freely in their blood. Based on biopsy results of these biomarkers and other indications, they then are matched to a sub-study, or treatment arm whose therapies they are seen as most likely to respond to. Known as the PC-BETS trial and conducted by the Canadian Cancer Trials Group (CCTG), the large umbrella study is recruiting up to 500 patients at sites across Canada. Information on contacts and locations can be found her
Subscribe or to access all post and page content.